Risk of adverse events, including those that may be due to zinc supplements Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Risk of adverse events, including those that may be due to zinc supplements Duration of · adults and children without colds
1 finding from 1 review
Proportion of participants developing a cold Duration of · adults and children without colds
1 finding from 1 review
Proportion with improved global symptom severity Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Risk of serious adverse events, including those that may be complications of the common cold · adults and children with colds and/or upper respiratory infections
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of colds developed Duration of · adults and children without colds
1 finding from 1 review
Duration of cold symptoms (days) · adults and children without colds
1 finding from 1 review
Standardised mean global symptom severity Duration of · adults and children without colds
1 finding from 1 review
Risk of serious adverse events, including those that may be complications of the common cold Duration of · adults and children without colds
1 finding from 1 review
Duration of cold symptoms (days) · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Risk of continuing colds at study end Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Standardised mean global symptom severity Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
All‐cause mortality · children with measles and pneumonia
It is very uncertain whether zinc changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Fever clearance time · children with measles and pneumonia
It is very uncertain whether zinc changes time to fever abatement compared with placebo (very low certainty).
1 finding from 1 review
Incidence of pneumonia Defined as patient admitted to hospital with a diagnosis of pneumonia Dose: 2 g per day · children aged 2 months to 59 months
Zinc supplementation may leads to lower pneumonia incidence compared with placebo (low certainty).
1 finding from 1 review
Pneumonia prevalence · children aged 2 months to 59 months
Zinc supplementation may leads to lower pneumonia prevalence compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Duration of cold symptoms (days) · patients with common cold
1 finding from 1 review
Intervention not reported
Severity of symptom score · patients with common cold
1 finding from 1 review
Intervention not reported
Incidence of common cold · patients with common cold
It is very uncertain whether the intervention changes incidence of common cold (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants symptomatic after 7 days of treatment · patients with common cold
It is very uncertain whether the intervention changes number of participants symptomatic after 7 days of treatment (very low certainty).
1 finding from 1 review